Livanova plc is petitioning CMS to remove the coverage with evidence development mandate for its vagus nerve stimulation device for treatment-resistant depression, aiming to streamline patient access without requiring costly clinical trials. The move could significantly reduce barriers to treatment and expedite therapeutic availability for this challenging mental health condition.